IPO Databook: Curis (CRIS US) - Aug 2026

95 Views12 Aug 2026 10:04

SUMMARY

Curis, Inc. is a biotechnology company developing emavusertib, an orally available small molecule inhibitor of IRAK4 and FLT3, evaluated in clinical studies for PCNSL and CLL.
Emavusertib received Orphan Drug Designation from FDA for PCNSL, AML, MDS and from EC for PCNSL, showing a 100% ORR in 5 BTK-naïve patients.
As of March 31, 2026, cash and cash equivalents were $15,001, with an accumulated deficit of $1.3 billion, raising substantial doubt about going concern.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream